LHRH agonist/antagonist
Phase 2Small molecule
Eli LillyLHRH agonist/antagonist is one of 84 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 2.
3
Indications
2
Total Trials
0
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Novantrone
PfizerPreclinical
Mekinist
NovartisPreclinical
LHRH agonist/antagonist
Eli LillyPhase 2
Trexall
Alnylam PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Duragesic
CCephalon
Preclinical
Prednisone/prednisolone
RochePreclinical
Triptorelin Pamoate
IpsenPreclinical
Osmitrol
BB. Braun Medical Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metastatic Prostate Cancer1 trial
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Terminated·—·Phase 2·NCT02582749·16 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LHRH agonist/antagonist. EMBL-EBI & Wellcome Sanger Institute.
- [4]